To evaluate the effects of TRF on CDAHFD-induced NASH pathology, we measured plasma liver injury markers, ALT and AST activity, and lipid content in the liver and evaluated inflammatory response and hepatic fibrosis. The gene discussed is GPT; the disease is Hepatic fibrosis.